Why can't I see VS Digital Health (VSDH) pricing before I commit?

The pricing transparency problem shows up at the worst moment: a patient is ready to start semaglutide or tirzepatide, and you cannot tell them the cost because ConnectRxCare does not show landed per-vial pricing before you are onboarded. You either guess, quote a padded number to be safe, or tell the patient you will follow up — and follow-ups are where conversions go to die.

For owners, the same opacity makes margin planning a moving target. If the cost per vial is only knowable after a HubSpot intake and custom quote — and can shift with volume tiers or revenue-share terms — building a predictable cash-pay program means working from estimates rather than numbers.

VSDH advertises volume-negotiated wholesale rates with no middleman markup, but its public site directs clinics to request a custom quote instead of listing per-vial prices as of June 2026. That fits a white-label business model where rates are set through negotiation and revenue share rather than a self-serve pass-through catalog. It can yield good pricing at volume, but the trade-off is that you do not see a number until you ask for one.

When you evaluate VSDH for a clinic that already prescribes — not a net-new D2C brand — the right questions are about timing and visibility: how long from HubSpot contact to a usable quote, whether per-vial rates appear inside ConnectRxCare afterward, and how rates change as volume moves between tiers. If pricing never surfaces in the ordering tool, the quote delay repeats every time a new SKU or tier comes up.

The delay disappears when pricing is visible at the point of decision. Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout, with the facilitation fee disclosed at payment, so a clinician can quote a patient in the room and an owner can model margin from real numbers. There is no sales gate between you and the cost of the medication you are about to order.

Pass-through pricing is the structural difference: instead of a negotiated rate hidden in a partner agreement, you see the 503A cost and the disclosed fee. The evaluation test is whether you can answer what does this vial cost without submitting a contact form. When the catalog answers that question, the consult keeps moving and pricing stops being a bottleneck.